Clinical trials: Cancer Disease Progression
Sarcoma, Alveolar Soft Part
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS.
- Trial name
- NCT01391962
- Testing
- Cediranib, Sunitinib, Prochlorperazine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Small Cell Lung Cancer, Non Small Cell Lung Cancer
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following…
- Conditions
- Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
- Trial name
- NCT07001995
- Testing
- limertinib, etoposide and carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Breast Neoplasms
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or…
- Trial name
- NCT00073528
- Testing
- Lapatinib, Letrozole
- Where
- 278 sites in United States, Argentina and 27 more
- Volunteers
- 1,286 people
- Sponsor
- Novartis Pharmaceuticals
Progression-free Survival, Overall Survival
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine.
- Conditions
- Progression-free Survival, Overall Survival, Toxicity
- Trial name
- PDVPSTS (NCT03342300)
- Testing
- pegylated liposomal doxorubicin, pirarubicin
- Where
- China
- Sponsor
- Peking University People's Hospital
Colorectal Cancer
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX or FOLFOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin.
- Trial name
- NCT01077739
- Testing
- fluorouracil (5FU), leucovorin, bevacizumab [Avastin]
- Where
- 28 sites in Belgium
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Solid Tumor Cancer
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and…
- Conditions
- Metastatic Cancer, Solid Tumor Cancer, Lymphoproliferative Disorders, Anxiety
- Trial name
- NCT06042400
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Boulder
Cervical Intraepithelial Neoplasia
Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia
The investigators hypothesis is HPV integration could result in expression of oncogene transcripts, and not only constitutive expression but also the level of expression will be decisive for transformation and the maintenance of…
- Trial name
- NCT02198365
- Where
- Taiwan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Cathay General Hospital
Pancreatic Cancer, Metastatic Pancreatic Cancer
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
- Trial name
- NCT04133155
- Testing
- nab paclitaxel plus gemcitabine
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Asan Medical Center
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of care as long as there are no contraindications to trastuzumab.
- Trial name
- NCT01835236
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- 71 sites in France, Germany and 2 more
- Volunteers
- 208 people
- Sponsor
- Swiss Cancer Institute
NSCLC, NSCLC Stage IV
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereotactic ablative radiotherapy (SABR) in oncogene addicted and non-oncogene addicted synchronous…
- Conditions
- NSCLC, NSCLC Stage IV, Oligometastatic Disease, Non Small Cell Lung Cancer
- Trial name
- STARTNEWERA-OM (NCT06207292)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Radiotherapy Oncology Centre "Santa Maria" Hospital
Invasive Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
This trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (MRI) works in determining radiation necrosis and tumor progression in participants with cancer that has spread to the brain and are being…
- Trial name
- NCT03680144
- Testing
- Dynamic Susceptibility Contrast-MRI (DSC-MRI), Magnetic Resonance Imaging (MRI)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Head and Neck Cancer
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had…
- Trial name
- NCT00617734
- Testing
- IMC-A12 (cixutumumab), cetuximab (Erbitux ®)
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Sentinel Lymph Node Biopsy, Locoregional Neoplasm Recurrence
SLNB After Neoadjuvant Treatment in Node Positive Patients
From May 2016 till May 2018 all breast cancer patients with operable disease submitted to surgery after neoadjuvant treatment would be divided in four groups considering initially clinical axillary stage, axillary procedure that…
- Conditions
- Sentinel Lymph Node Biopsy, Locoregional Neoplasm Recurrence, Progression, Disease
- Trial name
- NCT03833960
- Volunteers
- 65 people
- Sponsor
- Clinical Hospital Center Rijeka
HER2-positive Breast Cancer
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer…
- Trial name
- TUC-TOC (NCT05955170)
- Testing
- Tucatinib in Combination of Oral VP16 and trastuzumab
- Where
- 13 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut Curie
HCC, Liver Tumor
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
Magnetic resonance imaging (MRI) has been widely used for small liver lesion detection and characterization. In patients who undergo RFA, MRI is often performed before RFA, whereas immediate technical success is usually assessed…
- Trial name
- NCT02985034
- Testing
- RFA
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Seoul National University Hospital
Prostate Cancer Metastatic, Prostate Cancer
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
The main objective of the trial is to assess impact of maintenance therapy with ODM-201 on radiographic progression-free survival (rPFS) of patients with mCRPC pretreated with novel hormonal agents who have non-progressive…
- Trial name
- NCT02933801
- Testing
- ODM-201
- Where
- 32 sites in France, Italy and 2 more
- Volunteers
- 92 people
- Sponsor
- Swiss Cancer Institute
Non-small Cell Lung Cancer
Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors
The investigators propose a non-invasive prognostic tool for TKIs resistance in patients with stage IV EGFR-mutant non-small cell lung cancer (NSCLC) by computed tomography phenotypic features, which can be conveniently…
- Trial name
- NCT02851329
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.